All articles by Swagath Bandhakavi
Swagath Bandhakavi
J&J’s Tremfya meets primary and secondary endpoints in Phase 3b PsA trial
The trial showed that the medication effectively reduces signs, symptoms, and structural damage progression compared to a placebo after 24 weeks
Astellas, JFCR partner to drive translational oncology development
The collaboration seeks to fast-track the development of treatments targeting cancers that do not respond to current therapeutic options
Eton Pharmaceuticals out-licenses Increlex global rights to Esteve
Increlex is a biologic therapy for children aged 2–18 with severe primary insulin-like growth factor-1 deficiency
Alnylam’s Qfitlia receives FDA nod for haemophilia A and B treatment
Qfitlia is approved for routine prophylaxis in individuals aged 12 and older, both adults and children, with haemophilia A or B, regardless of the presence of factor VIII or IX inhibitors
Bio-Thera partners with Dr. Reddy’s for commercialisation of proposed biosimilars
Under the partnership, Bio-Thera will handle the development, manufacturing, and supply of the biosimilars, while Dr. Reddy’s will oversee regulatory approvals and commercial operations in specific countries
Kelun-Biotech’s SKB107 gains approval for bone metastases clinical trials in China
SKB107 is designed to target bone metastases in solid tumours using a small molecule targeting ligand integrated with conjugation technology, a chelator, and a therapeutic radionuclide
Sermonix and Regor to collaborate on advancing breast cancer drug discovery
The collaboration will combine Sermonix’s clinical drug development expertise with Regor’s computational discovery technology to advance metastatic breast cancer treatment
Duke-NUS and NUS Medicine unveil metabolomics research hub in Singapore
Based at Duke-NUS and NUS Medicine, the research centre focuses on metabolomics to enhance disease detection and precision medicine
Novartis gains first FDA approval for Fabhalta in C3 glomerulopathy
The approval enables Fabhalta to reduce proteinuria in patients with C3G, offering the first authorised treatment for the condition
Servier to license Black Diamond’s BDTX-4933 in $780m oncology deal
Servier will lead the clinical development and global commercialisation of BDTX-4933 for multiple indications, including NSCLC, under the agreement